Overview
24-hour IOP-lowering Effect of Brimonidine 0.1%
Status:
Completed
Completed
Trial end date:
2009-02-01
2009-02-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study will evaluate the efficacy and safety of brimonidine 0.1% three-times daily in patients with glaucoma or ocular hypertensionPhase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
AllerganTreatments:
Brimonidine Tartrate
Criteria
Inclusion Criteria:- patients with open-angle glaucoma or ocular hypertension
Exclusion Criteria:
- allergy to brimonidine
- inability to complete 24 hour stay for monitoring